Preview

Современная ревматология

Расширенный поиск

Инфекция, вызываемая вирусом Herpes zoster, и ревматические заболевания: современное состояние проблемы

https://doi.org/10.14412/1996-7012-2016-3-69-76

Полный текст:

Аннотация

Настоящий обзор посвящен проблеме инфекции, вызываемой реактивацией вируса Herpes zoster (HZ), при ревматических заболеваниях (РЗ). По данным абсолютного большинства исследований, частота HZ-инфекции при РЗ превышает популяционную в 2–10 раз. В качестве факторов риска выделяют возраст, пол, прием глюкокортикоидов, длительность и тяжесть заболевания. Несомненно, важной является проблема вакцинации против HZ-инфекции пациентов с РЗ. На сегодняшний день представляет интерес изучение эффективности и безопасности новой адъювантной HZ/su-вакцины у пациентов с РЗ.

Об авторах

Д. В. Буханова
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой», Москва, Россия 115522, Москва, Каширское шоссе, 34А
Россия


Б. С. Белов
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой», Москва, Россия 115522, Москва, Каширское шоссе, 34А
Россия


Литература

1. Kaslow RA, Stanberry LR, LeDuc JW. Viral infection of humans: epidemiology and controls. 5th ed. New York: Springer Science Business Media; 2014. P. 971-96.

2. Chen N, Li Q, Zhang Y, et al. Vaccination for preventing postherpetic neuralgia. Cochrane Database Syst Rev. 2011 Mar 16;(3):CD007795. doi: 10.1002/14651858. CD007795.pub2.

3. U.S. Department of Health & Human Services, Shingles (Herpes Zoster). http://www.cdc.gov/shingles/index.html.

4. Pinchinat S, Cebrian-Cuenca AM, Bricout H, et al. Similar herpes zoster incidence across Europe: results from a systematic literature review. BMC Infect Dis. 2013 Apr 10;13:170. doi: 10.1186/1471-2334-13-170.

5. Forbes HJ, Bhaskaran K, Thomas SL, Smeeth L. Quantification of risk factors for herpes zoster: population based case-control study. BMJ. 2014 May 13;348:g2911. doi: 10.1136/bmj.g2911.

6. Wolfe F, Michaud K, Chakravarty EF. Rates and predictors of herpes zoster in patients with rheumatoid arthritis and noninflammatory musculoskeletal disorders. Rheumatology (Oxford). 2006;45(11):1370-5.

7. Smitten AL, Choi HK, Hochberg MC, et al. The risk of herpes zoster in patientswith rheumatoid arthritis in the United States and the United Kingdom. Arthritis Rheum. 2007 Dec 15;57(8):1431-8.

8. Widdifield J, Bernatsky S, Paterson JM, et al. Serious infections in a population-based cohort of 86,039 seniors with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2013 Mar;65(3):353-61. doi: 10.1002/acr.21812.

9. McDonald JR, Zeringue AL, Caplan L, et al. Herpes zoster risk factors in a national cohort of veterans with rheumatoid arthritis. Clin Infect Dis. 2009 May 15;48(10):1364-71. doi: 10.1086/598331.

10. Veetil BM, Myasoedova E, Matteson EL, et al. Incidence and time trends of herpes zoster in rheumatoid arthritis: a populationbased cohort study. Arthritis Care Res (Hoboken). 2013 Jun;65(6):854-61. doi: 10.1002/acr.21928.

11. Nakajima A, Urano W, Inoue E, et al. Incidence of herpes zoster in Japanese patients with rheumatoid arthritis from 2005 to 2010. Mod Rheumatol. 2015 Jul;25(4):558-61. doi: 10.3109/14397595.2014.984829.

12. Antonelli MA, Moreland LW, Brick JE. Herpes zoster in patients with rheumatoid arthritis treated with weekly, low-dose methotrexate. Am J Med. 1991;90(3):295-8.

13. Segan J, Staples MP, March L, et al. Risk factors for herpes zoster in rheumatoid arthritis patients: the role of tumour necrosis factor- α inhibitors. Intern Med J. 2015 Mar; 45(3):310- 8. doi: 10.1111/imj.12679.

14. Strangfeld A, Listing J, Herzer P, et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA. 2009;301(7):737-44.

15. Pappas DA, Hooper MM, Kremer JM, et al. Herpes zoster reactivation in patients with rheumatoid arthritis: analysis of disease characteristics and disease modifying anti- rheumatic drugs. Arthritis Care Res (Hoboken). 2015 Dec;67(12):1671-8. doi: 10.1002/ acr.22628.

16. Yun H, Xie F, Delzell E, et al. Risks of herpes zoster in patients with rheumatoid arthritis according to biologic disease-modifying therapy. Arthritis Care Res (Hoboken). 2015 May;67(5):731-6. doi: 10.1002/acr.22470.

17. Galloway JB, Mercer LK, Moseley A, et al. Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 2013;72(2):229-34.

18. Winthrop KL, Baddley JW, Chen L, et al. Association between the initiation of anti- TNF therapy and the risk of herpes zoster. JAMA. 2013 Mar 6;309(9): 887-95. doi: 10.1001/jama.2013.1099.

19. Dewedar AM, Shalaby MA, Al-Homaid S, et al. Lack of adverse effect of anti-tumor necrosis factor-alpha biologics in treatment of rheumatoid arthritis: 5 years follow- up. Int J Rheum Dis. 2012;15(3):330-5.

20. Wendling D, Streit G, Toussirot E, Prati C. Herpes zoster in patients taking TNFalpha antagonists for chronic inflammatory joint disease. Joint Bone Spine. 2008 Oct;75(5):540-3. doi: 10.1016/j.jbspin.2007.10.011. Epub 2008 Jul 31.

21. Winthrop KL, Yamanaka H, Valdez H, et al. Herpes Zoster and Tofacitinib Therapy in Patients With Rheumatoid Arthritis. Arthritis Rheumatol. 2014 Oct;66(10):2675-84. doi: 10.1002/art.38745.

22. Curtis JR, Xie F, Yun H, et al. Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis. Ann Rheum Dis. 2016 Apr 25. pii: annrheumdis-2016-209131. doi: 10.1136/annrheumdis-2016-209131. [Epub ahead of print].

23. Borba EF, Ribeiro AC, Martin P, et al. Incidence, risk factors, and outcome of Herpes zoster in systemic lupus erythematosus. J Clin Rheumatol. 2010 Apr;16(3):119-22. doi: 10.1097/RHU.0b013e3181d52ed7.

24. Manzi S, Kuller LH, Kutzer J, et al. Herpes zoster in systemic lupus erythematosus. J Rheumatol. 1995 Jul;22(7):1254-8.

25. Kahl LE. Herpes zoster infections in systemic lupus erythematosus: risk factors and outcome. J Rheumatol. 1994 Jan;21(1):84-6.

26. Moutsopoulos HM, Gallagher JD, Decker JL, et al. Herpes zoster in patients with systemic lupus erythematosus. Arthritis Rheum. 1978 Sep-Oct;21(7):798-802.

27. Hellman DB, Petri M, Whiting-O’Keefe Q. Fatal infections in systemic lupus erythematosus: the role of opportunistic organisms. Medicine (Baltimore). 1987 Sep;66(5):341-8.

28. Moga I, Formiga F, Canet R, et al. Herpes-zoster virus infection in patients with systemic lupus erythematosus. Rev Clin Esp. 1995 Aug;195(8):530-3.

29. Chakravarty EF, Michaud K, Katz R, Wolfe F. Increased incidence of herpes zoster among patients with systemic lupus erythematosus. Lupus. 2013 Mar;22(3): 238-44. doi: 10.1177/0961203312470186.Epub 2012 Dec 20.

30. Chen HH, Chen YM, Chen TJ, et al. Risk of herpes zoster in patients with systemic lupus erythematosus: a three-year follow-up study using a nationwide population-based cohort. Clinics (Sao Paulo). 2011;66(7):1177-82.

31. Kang TY, Lee HS, Kim TH, et al. Clinical and genetic risk factors of herpes zoster in patients with systemic lupus erythematosus. Rheumatol Int. 2005 Mar;25(2):97-102. Epub 2003 Oct 31. doi: 10.1007/s00296-003-0403-3.

32. Skare TL, Dagostini JS, Zanardi PI, Nisihara RM. Infections and systemic lupus erythematosus. Einstein (Sao Paulo). 2016 Mar;14(1):47-51. doi: 10.1590/S1679- 45082016AO3490.

33. Chakravarty EF, Odell J, Rasmussen A, et al. Varicella Zoster Reactivation in Patients with Primary Sjö gren’s Syndrome and SLE [abstract]. Arthritis Rheumatol. 2015;67 (suppl 10).

34. Chen JY, Wang LK, Feng PH, et al. Risk of Shingles in Adults with Primary Sjö gren's Syndrome and Treatments: A Nationwide Population-Based Cohort Study. PLoS One. 2015 Aug 25;10(8):e0134930. doi: 10.1371/journal.pone.0134930. eCollection 2015.

35. Tsai SY, Lin CL, Wong YC, et al. Increased Risk of Herpes Zoster Following Dermatomyositis and Polymyositis. Medicine (Baltimore). 2015 Jul; 94(28): e1138. doi: 10.1097/MD.0000000000001138.

36. Chen IJ, Tsai WP, Wu YJ, et al. Infections in polymyositis and dermatomyositis: analysis of 192 cases. Rheumatology (Oxford). 2010 Dec;49(12):2429-37. doi: 10.1093/rheumatology/keq279. Epub 2010 Sep 13.

37. Fardet L, Rybojad M, Gain M, et al. Incidence, risk factors, and severity of herpesvirus infections in a cohort of 121 patients with primary dermatomyositis and dermatomyositis associated with a malignant neoplasm. Arch Dermatol. 2009 Aug; 145(8):889-93. doi: 10.1001/archdermatol.2009.152.

38. Zisman D, Bitterman H, Shalom G, et al. Psoriatic arthritis treatment and the risk of herpes zoster. Ann Rheum Dis. 2016 Jan;75(1):131-5. doi: 10.1136/annrheumdis- 2013- 205148.

39. Wung PK, Holbrook JT, Hoffman GS, et al. Herpes zoster in immunocompromised patients: incidence, timing, and risk factors. WGET Research Group. Am J Med. 2005 Dec;118(12):1416.

40. Foocharoen C, Siriphannon Y, Mahakkanukrauh A, et al. Incidence rate and causes of infection in Thai systemic sclerosis patients. Int J Rheum Dis. 2012 Jun;15(3):277-83. doi: 10.1111/j.1756-185X.2012.01728.x

41. Gagliardi AM, Gomes Silva BN, Torloni MR, Soares BG. Vaccines for preventing herpes zoster in older adults. Cochrane Database Syst Rev. 2012 Oct 17;10:CD008858. doi: 10.1002/14651858. CD008858.pub2.

42. Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005 Jun 2;352(22):2271-84.

43. Schmader KE, Levin MJ, Gnann JW, et al. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50–59years. Clin Infect Dis. 2012 Apr;54(7):922-8. doi: 10.1093/cid/cir970. Epub 2012 Jan 30.

44. Morrison VA, Johnson GR, Schmader KE, et al. Long-term persistence of zoster vaccine efficacy. Clin Infect Dis. 2015 Mar 15;60(6):900-9. doi: 10.1093/cid/ciu918. Epub 2014 Nov 20.

45. Curtis JR, Turner A, Thomas C, et al. Safety, Clinical and Immunologic Effectiveness of the Live Zoster Vaccine Administered to Patients Receiving Anti- TNF Biologics [abstract]. Arthritis Rheumatol. 2015;67(Suppl 10).

46. Yun H, Xie F, Baddley J, et al. Long Term Effectiveness of Herpes Zoster Vaccine Among Patients with Autoimmune and Inflammatory Diseases [abstract]. Arthritis Rheumatol. 2015;67(Suppl 10).

47. Malavige GN, Jones L, Black AP, Ogg GS. Varicella zoster virus glycoprotein Especific CD4+ T cells show evidence of recent activation and effector differentiation, consistent with frequent exposure to replicative cycle antigens in healthy immune donors. Clin Exp Immunol. 2008 Jun;152(3):522-31. doi: 10.1111/j.1365-2249.2008.03633.x. Epub 2008 Mar 20.

48. Laing KJ, Russell RM, Dong L, et al. Zoster vaccination increases the breadth of CD4+ T cells responsive to varicella zoster virus. J Infect Dis. 2015 Oct 1;212(7):1022-31. doi: 10.1093/infdis/jiv164. Epub 2015 Mar 17.

49. Lal H, Cunningham AL, Godeaux O, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015 May 28;372(22):2087-96. doi: 10.1056/NEJMoa1501184. Epub 2015 Apr 28.

50. Stadtmauer EA, Sullivan KM, Marty FM, et al. A Phase 1/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients. Blood. 2014 Nov 6;124(19):2921-9. doi: 10.1182/blood-2014-04-573048. Epub 2014 Sep 18.

51. Berkowitz EM, Moyle G, Stellbrink HJ, et al. Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: a Phase 1/2a randomized, placebo-controlled study. J Infect Dis. 2015 Apr 15;211(8):1279-87. doi: 10.1093/infdis/jiu606. Epub 2014 Nov 3.


Для цитирования:


Буханова Д.В., Белов Б.С. Инфекция, вызываемая вирусом Herpes zoster, и ревматические заболевания: современное состояние проблемы. Современная ревматология. 2016;10(3):69-76. https://doi.org/10.14412/1996-7012-2016-3-69-76

For citation:


Bukhanova D.V., Belov B.S. Herpes zoster virus infection and rheumatic diseases: Current state of the problem. Modern Rheumatology Journal. 2016;10(3):69-76. (In Russ.) https://doi.org/10.14412/1996-7012-2016-3-69-76

Просмотров: 281


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1996-7012 (Print)
ISSN 2310-158X (Online)